Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts' Meeting Septembe...(200256 193515 Accumulated o...),Health

Accumulated other comprehensive loss (431) (1,903)

Treasury stock, at cost 889,245

and 848,588 shares (33,188) (32,178)

Total stockholders' equity 421,009 377,188

Total liabilities and stockholders' equity $810,418 $736,030

* $200,000 Senior Subordinated Convertible Notes due in 2010 have been

reclassified as a current liability due to pending litigation.

PAR PHARMACEUTICAL COMPANIES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Data)

(Unaudited)

Three months ended Twelve months ended

December December December December

31, 31, 31, 31,

2006 2005 2006 2005

Revenues:

Net product sales $176,807 $94,338 $705,378 $412,126

Other product related

revenues 6,826 3,740 19,790 20,130

Total revenues 183,633 98,078 725,168 432,256

Cost of goods sold 124,680 77,557 507,220 277,554

Gross margin 58,953 20,521 217,948 154,702

Operating expenses:

Research and development 18,459 14,569 62,442 62,497

Selling, general and

administrative 37,151 24,330 148,488 92,309

Intangible assets impairment 1,100 - 1,100 6,999

Settlements, net (1,804) - (1,804) -

Total operating expenses 54,906 38,899 210,226 161,805

Operating
'/>"/>